Neurogene Inc.

NGNE Nasdaq SEC CIK 1404644
Follow Neurogene Weekly email: filings, results, news

Financials

Reported figures only · latest: Q2 2026 USD · US GAAP
Net income −$34.5M −56.6% vs same quarter last year
EPS, diluted −$1.53 −45.7% vs same quarter last year
Operating cash flow −$23.8M −22.1% vs same quarter last year
Operating income −$36.7M −40.6% vs same quarter last year
Revenue by quarter
$0
$0
$0
$0
$0
Q3 24 Q4 24 Q2 25 Q3 25 Q4 25

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income15 fiscal years
  • Revenue
  • Net income
−$100M−$50M$0$50MFY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearRevenueNet income
FY25$0−$90.4M
FY24$925K−$75.1M
FY23$0−$36.3M
FY22-−$55.2M
FY21-−$60.7M
FY20-−$33.3M
FY19-−$69.4M
FY18$25M−$31.6M
FY17-−$50.2M
FY16-−$37M
FY15-−$21.9M
FY14-−$24M
FY13-−$8.7M
FY12-−$7.7M
FY11--
Free cash flowOperating cash flow minus capital expenditure
−$80M−$60M−$40M−$20M$0FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearFree cash flow
FY25−$78.4M
FY24−$71.4M
FY23−$51.7M
FY22−$55.1M
FY21−$50.8M
FY20−$26.8M
FY19−$16.3M
FY18−$31.6M
FY17−$45.2M
FY16−$30.9M
FY15−$20.3M
FY14−$17.6M
FY13−$7.8M
FY12−$7.2M
FY11-

News

No stories filed under Neurogene yet - coverage appears here as the news feed clusters it.